Home LiteratureArticle Details
PMID: 9797254 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model.

Antimicrobial agents and chemotherapy ·Vol. 42 ·No. 11 ·1998-11-00 ·Pages 3047-8

Brooks JV, Orme IM

Abstract

Once-weekly therapy with combinations of isoniazid plus a rifamycin was tested in the mouse low-dose aerosol infection model against two strains of Mycobacterium tuberculosis. Combinations of isoniazid and rifalizil and isoniazid and rifapentine were both highly effective. These animal model data thus support the evaluation of these regimens under clinical conditions.

MeSH Terms
Aerosols Animals Antitubercular Agents/administration & dosage Drug Administration Schedule Drug Therapy, Combination Female Isoniazid/administration & dosage Mice Mice, Inbred C57BL Rifamycins/administration & dosage Tuberculosis/drug therapy
Chemicals
Aerosols Antitubercular Agents Rifamycins Isoniazid
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Brooks J V
Mycobacteria Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523, USA.
Orme I M
References (25)
25 references, click to expand
  1. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis.
    Tubercle. 1987 Sep;68(3):183-93 PMID: 2834843
  2. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis.
    N Engl J Med. 1998 Mar 5;338(10):633-9 PMID: 9486991
  3. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.
    Am Rev Respir Dis. 1990 Mar;141(3):626-30 PMID: 2155555
  4. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.
    Ann Intern Med. 1990 Mar 15;112(6):407-15 PMID: 2106816
  5. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
    Am Rev Respir Dis. 1992 Jan;145(1):212-4 PMID: 1309967
  6. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection).
    Eur Respir J. 1992 Jun;5(6):680-4 PMID: 1321054
  7. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.
    Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1541-6 PMID: 8256897
  8. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.
    Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1355-62 PMID: 7952564
  9. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.
    Antimicrob Agents Chemother. 1994 Oct;38(10):2245-8 PMID: 7840552
  10. Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.
    Antimicrob Agents Chemother. 1994 Oct;38(10):2346-50 PMID: 7840568
  11. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group.
    Tuber Lung Dis. 1994 Oct;75(5):341-7 PMID: 7841427
  12. WHO calls for action against TB.
    Science. 1995 Mar 24;267(5205):1763 PMID: 7892595
  13. Eleven years of community-based directly observed therapy for tuberculosis.
    JAMA. 1995 Sep 27;274(12):945-51 PMID: 7674524
  14. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 1995 Oct;39(10):2295-303 PMID: 8619585
  15. Directly-observed therapy, patient education and combined drug formulations: complementary, not alternative, strategies in tuberculosis control.
    Tuber Lung Dis. 1996 Apr;77(2):101 PMID: 8762840
  16. Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam.
    Tuber Lung Dis. 1996 Apr;77(2):178-83 PMID: 8762855
  17. Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994.
    Am J Public Health. 1996 Aug;86(8):1094-7 PMID: 8712267
  18. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 1996 Dec;40(12):2809-12 PMID: 9124846
  19. Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance.
    Thorax. 1996 Nov;51(11):1130-3 PMID: 8958898
  20. Efficacy of twice weekly treatment for tuberculosis given under direct observation in Africa.
    Trans R Soc Trop Med Hyg. 1997 Jan-Feb;91(1):87-9 PMID: 9093639
  21. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis.
    Chest. 1997 Jul;112(1):63-70 PMID: 9228359
  22. Combating tuberculosis--lessons learnt from a rural community project in the Klein Drakenstein area of the Western Cape.
    S Afr Med J. 1997 Aug;87(8 Suppl):1042-7 PMID: 9323428
  23. Sociological and anthropological factors related to the community management of tuberculosis in the Western Cape communities of Ravensmead and Uitsig.
    S Afr Med J. 1997 Aug;87(8 Suppl):1047-51 PMID: 9323429
  24. Compliance with tuberculosis drug regimens: incentives and enablers offered by public health departments.
    Am J Public Health. 1997 Dec;87(12):2014-7 PMID: 9431294
  25. Antimycobacterial activity in vivo of LM427 (rifabutin).
    Am Rev Respir Dis. 1988 Nov;138(5):1254-7 PMID: 2849349
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
DOI
10.1128/AAC.42.11.3047
Published
1998-11-00
Pages
3047-8
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC105994
Subset
IM
Grants
NIAID NIH HHS · N01 AI045244 · United States
NIAID NIH HHS · AI-45239 · United States
External Links
PubMed source DOI: 10.1128/AAC.42.11.3047 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2